COMORBIDITY PATTERNS AND THEIR ASSOCIATION WITH GALLSTONE DISEASE IN THE ELDERLY POPULATION: (A POPULATION-BASED STUDY IN THE FERGANA VALLEY, UZBEKISTAN)
DOI:
https://doi.org/10.5281/zenodo.23367048Keywords:
gallstone disease, cholelithiasis, comorbidity, multimorbidity, older adults, risk factors, metabolic disorders, epidemiology, Fergana Valley, UzbekistanAbstract
Background. Gallstone disease (GSD) is one of the most prevalent disorders of the biliary system and represents an important clinical and public health problem, particularly in older adults. Age-related metabolic changes and the accumulation of chronic diseases may substantially modify the risk, clinical presentation, and course of GSD. The assessment of comorbidity patterns may therefore contribute to the earlier identification of high-risk individuals and the optimization of preventive strategies. Objective. To evaluate the structure of comorbid conditions and their association with gallstone disease among adults aged 60–75 years in the Fergana Valley of Uzbekistan. Materials and Methods. A population-based observational study was conducted among residents aged 60–75 years in Fergana, Uzbekistan. Epidemiological, clinical, laboratory, instrumental, and statistical methods were used. Information on demographic characteristics, metabolic risk factors, cardiovascular diseases, gastrointestinal and hepatobiliary disorders, respiratory diseases, renal disorders, and other chronic conditions was collected from clinical examinations, preventive screening data, and outpatient medical records. Statistical analysis included comparisons between study groups, assessment of categorical variables using the χ² test, calculation of relative risk (RR), 95% confidence intervals (95% CI), and significance levels. Results. The analysis demonstrated a substantial burden of concomitant chronic diseases among older individuals evaluated for gallstone disease. Cardiovascular, gastroenterological, and hepatobiliary comorbidities were among the most frequently identified accompanying conditions. In the comparative analysis, cardiovascular comorbidity was recorded in 17 individuals in the main group and 6 in the control group, gastroenterological comorbidity in 16 and 1, and hepatobiliary comorbidity in 21 and 9 individuals, respectively. Respiratory comorbidity was observed in 10 versus 2 individuals, whereas hematological comorbidity was detected in 2 versus 1. These findings indicate a clustering of chronic metabolic and organ-system disorders in individuals with gallstone disease and suggest an important relationship between multimorbidity and the clinical and epidemiological profile of GSD in older adults. Conclusion. Gallstone disease in adults aged 60–75 years is associated with a considerable burden of comorbid conditions, particularly cardiovascular, gastroenterological, and hepatobiliary disorders. Comprehensive assessment of comorbid conditions should be incorporated into risk stratification and preventive monitoring of older individuals with or at increased risk of gallstone disease.References
1. Wang, K., Liu, Z., Tang, R., Sha, Y., Wang, Z., Chen, Y., et al. (2025). Gallstones in the era of metabolic syndrome: pathophysiology, risk prediction, and management. Cureus. 2025;17(3). doi:10.7759/cureus.80541. PMID: 40225487. https://doi.org/10.7759/cureus.80541
2. Tang, Y. F., Su, Y. T., Liang, L. J., Feng, Y., Huang, X. J., Xiang, X. L., et al. (2025). Association between metabolic dysfunction and gallstone disease in U.S. adults: an analysis of the National Health and Nutrition Examination Survey. J Dig Dis, 26(3-4), 158–169. https://doi.org/10.1111/1751-2980.13349
3. Chen, J., Liu, Z. T., Lyu, J. T., & Jiang, G. P. (2024). Impact of metabolic disorders on gallstone disease and perioperative recovery after laparoscopic cholecystectomy. Hepatobiliary Pancreat Dis Int, 23(6), 604–612. https://doi.org/10.1016/j.hbpd.2024.08.001
4. Uche-Anya, E., Ha, J., Balasubramanian, R., Rexrode, K. M., & Chan, A. T. (2024). Metabolomic profiles of incident gallstone disease. BMJ Open Gastroenterol. 2024;11(1). doi:10.1136/bmjgast-2024-001417. PMID: 39209332. 39209332. https://doi.org/10.1136/bmjgast-2024-001417
5. Rodriguez Gatta D, et al. Sex disparities in gallstone disease: insights from the MAUCO prospective population-based cohort study. BMJ Open Gastroenterol. 2024;11(1). doi:10.1136/bmjgast-2024-001457. PMID: 39343441.
6. Rahimi, R., Heidari-Soureshjani, S., Sherwin, C. M. T., Kasiri, K., & Rahimian, G. (2025). The association between gallstone disease and cardiovascular disease: a systematic review and meta-analysis. Rev Recent Clin Trials, 20(2), 142–152. https://doi.org/10.2174/0115748871326450240926072451
7. Hasan, et al. Gallstones as a predictor of elevated cardiovascular disease risk: a meta-analysis and metaregression of over 7.4 million participants. 2025. PMID: 40106516.
8. Rahimi, R., Masoumi, S., Badali, A., Jafari, N., Heidari-Soureshjani, S., & Sherwin, C. M. T. (2024). Association between gallstone disease and risk of mortality of cardiovascular disease and cancer: a systematic review and meta-analysis. 47-58. doi:10.2174/011871529X298791240607041246. https://doi.org/10.2174/011871529X298791240607041246
9. Upala, S., Sanguankeo, A., & Jaruvongvanich, V. (2017). Gallstone disease and the risk of cardiovascular disease: a systematic review and meta-analysis of observational studies. Scand J Surg, 106(1), 21–27.
10. Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2022. PMID: 36506064.
11. Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the US. Hepatology. 2023. PMID: 36631004.
12. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-181.
13. Lammert, F., Gurusamy, K., Ko, C. W., Miquel, J. F., Méndez-Sánchez, N., Portincasa, P., et al. (2016). Gallstones. Nat Rev Dis Primers. 2016;2:16024.
14. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-
15. Stinton, L. M., & Shaffer, E. A. (2012). Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver, 6(2), 172–187.
16. Di Ciaula A, Wang DQH, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71-80.
17. Wang, D. Q. H., Cohen, D. E., & Carey, M. C. (2009). Biliary lipids and cholesterol gallstone disease. J Lipid Res. 2009;50(Suppl).
18. Shaffer, E. A. (2005). Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep. 132–140.
19. Aune, D., & Vatten, L. J. (2016). Diabetes mellitus and the risk of gallbladder disease: a systematic review and metaanalysis of prospective studies. J Diabetes Complications, 30(2), 368–373.
20. Tsai, C. J., Leitzmann, M. F., Willett, W. C., & Giovannucci, E. L. (2006). Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut, 55(5), 708–714.
21. Tsai, C. J., Leitzmann, M. F., Willett, W. C., & Giovannucci, E. L. (2004). Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr, 80(1), 38–44.
22. Méndez-Sánchez, N., Chavez-Tapia, N. C., Motola-Kuba, D., Sanchez-Lara, K., Ponciano-Rodríguez, G., Baptista, H., et al. (2005). Metabolic syndrome as a risk factor for gallstone disease. World J Gastroenterol, 11(11), 1653–1657.
23. Biddinger, S. B., Haas, J. T., Yu, B. B., Bezy, O., Jing, E., Zhang, W., et al. (2008). Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med, 14(7), 778–782.
24. Marschall, H. U., & Einarsson, C. (2007). Gallstone disease. J Intern Med, 261(6), 529–542.
25. Everhart, J. E., Khare, M., Hill, M., & Maurer, K. R. (1999). Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology, 117(3), 632–639.
26. Shabanzadeh, D. M. (2018). Incidence of gallstone disease and complications. Curr Opin Gastroenterol, 34(2), 81–89.
27. Friedman, G. D. (1993). Natural history of asymptomatic and symptomatic gallstones. Am J Surg. 1993;165(4):399-.
28. Reshetnyak, V. I. (2012). Concept of the pathogenesis and treatment of cholelithiasis. World J Hepatol. 2012;4(2):18-.
29. Di Ciaula A, Garruti G, Frühbeck G, De Angelis M, de Bari O, Wang DQH, et al. The role of diet in the pathogenesis of cholesterol gallstones. Curr Med Chem. 2019;26(19):3620-3638.
30. Wang, D. Q. H., & Portincasa, P. (2017). editors. Gallstones: Recent Advances in Epidemiology, Pathogenesis, Diagnosis and Management. New York: Nova Science Publishers; 2017.
Downloads
Published
How to Cite
Issue
Section
